Cardioprotective Effects of Magnesium Sulfate in Patients Undergoing Primary Coronary Angioplasty for Acute Myocardial Infarction

Circulation Journal

Volumn 68, Issue 1, 2004, Pages 23-28

  Nakashima, Hiroshi ^a,b   Katayama, Toshiro ^a   Honda, Yukiharu ^a   Suzuki, Shin ^a   Yano, Katsusuke ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Acute myocardial infarction; Cardioprotection; Magnesium

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; MAGNESIUM SULFATE; SODIUM CHLORIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY REPERFUSION; DOPPLER ECHOGRAPHY; DRUG EFFECT; FEMALE; GUIDE WIRE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART VENTRICLE WALL MOTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PRESSURE; CARDIOTONIC AGENTS; COLLATERAL CIRCULATION; CORONARY VESSELS; FEMALE; HEART FUNCTION TESTS; HUMANS; MAGNESIUM SULFATE; MALE; MICROCIRCULATION; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES;

EID: 0942276918     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.23     Document Type: Article

References (28)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; ii: 397-402.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
3. Opie LH. Reperfusion injury and its pharmacological modification. Circulation 1989: 80: 1049-1062.
4. Steurer G, Yang P, Rao V, Mohl W, Glogar D, Smetana R, Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: Basic concepts and clinical implications. Am Heart J 1996; 132: 478-482.
5. Du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion. Circ Res 1992; 70: 960-967.
6. Garcia LA, Dejong SC, Martin SM, Smith RS, Buettner GR, Kerber RE. Magnesium reduces free radicals in an in vivo coronary occlusion-reperfusion model. J Am Coll Cardiol 1998; 32: 536-539.
7. Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 1995; 92: 2617-2621.
8. Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LR, Gerber MJ, Vogel RA, et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92: 2622-2626.
9. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-1558.
10. The Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: A randomised controlled trial. Lancet 2002;360: 1189-1196.
11. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: A prospective study. Circulation 1986; 74: 469-476.
12. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
13. Sheehan FH, Schofer J, Mathey DG, Kellett MA, Smith H, Bolson EL, et al. Measurement of regional wall motion from biplane contrast ventriculograms: A comparison of the 30 degree right anterior oblique and 60 degree left anterior oblique projections in patients with acute myocardial infarction. Circulation 1986; 74: 796-804.
14. White CW. Clinical applications of Doppler coronary flow reserve measurements. Am J Cardiol 1993; 71: 10D-16D.
15. Nahser PJ, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995; 91: 635-640.
16. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
17. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995; 91: 476-485.
18. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, et al. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneus transluminal coronary angioplasty versus tissue type plasminogen activator therapy. Am J Cardiol 1996; 78: 19-25.
19. Sakurai K, Watanabe J, Iwabuchi K, Koseki Y, Kon-no Y, Fukuchi M, et al. Comparison of the efficacy of reperfusion therapies for early mortality from acute myocardial infarction in Japan: Registry of Miyagi Study Group for AMI (MsAMI). Circ J 2003; 67: 209-214.
20. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no reflow' phenomenon. a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-228.
21. Yamamuro A, Akasaka T, Tamita K, Yamabe K, Katayama M, Takagi T, et al. Coronary flow velocity pattern immediately after percutaneus coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. Circulation 2002; 106: 3051-3056.
22. Antman EM. Magnesium in acute myocardial infarction: Overview of available evidence. Am Heart J 1996; 132: 487-494.
23. Santoro GM, Antoniucci D, Bolognese L, Valenti R, Buonamici P, Trapani M, et al. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J 2000; 140: 891-897.
24. Hongo M, Takenaka H, Uchikawa S, Nakatsuka T, Watanabe N, Sekiguchi M. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol 1995; 75: 246-250.
25. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
26. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300.
27. Sen S, Neuss H, Berg G, Nitsche K, Goddemeier T, Döring G. Beneficial effects of nicorandil in acute myocardial infarction: A placebo-controlled, double-blind pilot safety study. Br J Cardiol 1998; 5: 208-220.
28. Orita H, Fukasawa M, Abe H, Inui K, Hirooka S, Washio M. Preventive effect of post-ischemic reperfusion injury by terminal nicorandil-Mg cardioplegia. Nippon Kyoubu Geka Gakkai Zasshi 1991; 39: 2176-2180.